REVTORPYK™: A New FDA Approval for Gedatolisib/HPBCD composition
A new chapter in targeted cancer therapy On July 14, 2026, the U.S. FDA approved REVTORPYK™ (gedatolisib), developed by Celcuity,
A forum for researchers, students and applicants in the field of cyclodextrin technology
A new chapter in targeted cancer therapy On July 14, 2026, the U.S. FDA approved REVTORPYK™ (gedatolisib), developed by Celcuity,
This review on electrospinning investigates how this techniqe can be applied for delivering multiple drugs by allowing precise control over
Remdesivir (REM), a nucleoside analogue that has been approved for SARS-CoV-2 treatment, is poorly soluble in water and is currently
The Pharmaceutics 2027: From Biopharmaceutics to Clinical Pharmaceutics will take place in Barcelona, Spain from 28 to 30 June 2027. The following sessions are planned:
The Chinese group designed novel cyclodextrin-engineered bioinspired nanozyme (T-CD/Pt), and integrate it into a bi-regional microneedle (TP-MNs). Coupled with a
To enhance the bioactivity and antimicrobial properties of orthopedic Ti implants, a “three-in-one” coating was well designed and fabricated. A
This chapter offers a detailed overview of the structural features, different types, and chemical modifications of CDs and their derivatives,
The effects of native and modified CDs in human renal proximal tubule cells was studied using complementary imaging, flow cytometry,
In this collaborative teamwork, the cyclodextrins (CDs) are reviewed as important building blocks for polymeric systems in biomedical and environmental
Researchers from Mexico 🇲🇽 investigated dendronized βCD molecular containers designed to improve cellular uptake while maintaining biocompatibility. In human astrocyte